Overview

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.

Phase:

Phase 3

Details

Lead Sponsor:

Cumberland Pharmaceuticals
Theravance Biopharma Antibiotics, Inc.

Treatments:

Methicillin
Telavancin
Vancomycin